Zobrazeno 1 - 10
of 1 910
pro vyhledávání: '"ofatumumab"'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 5985-5996 (2024)
Zeinab Awada,1 Natasha Hameed,2 Asaff Harel1,2 1Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA; 2Northwell Comprehensive Multi
Externí odkaz:
https://doaj.org/article/f4f095d4b34142fbb18de24a7d9e89e8
Autor:
Rahul H. Dave, Heidi Crayton, Augusto Miravalle, Ming-Hui Tai, Kerri Wyse, Katherine Houghton, Abby Hitchens, Regina Berkovich
Publikováno v:
Neurology and Therapy, Vol 13, Iss 6, Pp 1737-1745 (2024)
Abstract Introduction Real-world data are required to provide a greater understanding of the impact of ofatumumab on the ability to mount an effective immune response following the receipt of approved COVID-19 vaccinations. This retrospective real-wo
Externí odkaz:
https://doaj.org/article/55ac2c4194cb4820af8902b3f4de5eab
Autor:
Wenlin Wu, Jie Hong, Yanping Ran, Wenxiao Wu, Haixia Zhu, Chi Hou, Yuanyuan Gao, Yulin Tang, Yinting Liao, Wen-Xiong Chen, Xiaojing Li
Publikováno v:
Heliyon, Vol 10, Iss 23, Pp e40680- (2024)
Ofatumumab (OFA) is an anti-CD20 antibody. We assessed the therapeutic potential of OFA in five pediatric anti-NMDAR encephalitis patients who showed poor responses to the first-line immunotherapy. OFA treatment showed clinical improvement including
Externí odkaz:
https://doaj.org/article/f95d2e96d1cc4894aaa2b32ddc59fdd9
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTBooster vaccinations against SARS-CoV-2 are recommended 6–12 months after the last dose or infection in elderly and high-risk groups. The present analysis aims to evaluate whether an interval shorter than 12 months is required in multiple s
Externí odkaz:
https://doaj.org/article/8180dc2e2dcc410bb0f523282f04e4e4
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Anti-kelchlike protein 11 (KLHL11) encephalitis was first reported in 2019. This disease is very rare. The prevalence is higher in men than in women. Few female cases have been described. The most common clinical manifestations of this disease are sy
Externí odkaz:
https://doaj.org/article/2ae28c694e0b47d6ba7a0f266b1e0b7c
Publikováno v:
Chinese Journal of Contemporary Neurology and Neurosurgery, Vol 24, Iss 6, Pp 491-496 (2024)
Objective To investigate the efficacy and safety of ofatumumab in the treatment of neuromyelitis optica spectrum disorders (NMOSDs). Methods The clinical data of 25 patients with NMOSDs hospitalized in The First Affiliated Hospital of Zhengzhou Unive
Externí odkaz:
https://doaj.org/article/0d3b6578511040b2b3dc8a313d70e839
Autor:
Jian Wang, QunHong Xiang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but treatable immune-mediated neuropathy. Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody that has shown promising efficacy in central demye
Externí odkaz:
https://doaj.org/article/576c1ff0faf84e318cd17cc5f9edde21
Autor:
Lena Prantl, Philipp Heider, Lisa Bergmeister, Katharina Calana, Jan-Paul Bohn, Dominik Wolf, Zoltan Banki, Andreas Bosch, Maximilian Plach, Georg Huber, Silke Schrödel, Christian Thirion, Heribert Stoiber
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Antibody-mediated complement-dependent cytotoxicity (CDC) on malignant cells is regulated by several complement control proteins, including the inhibitory complement factor H (fH). fH consists of 20 short consensus repeat elements (SCRs) with specifi
Externí odkaz:
https://doaj.org/article/fd7bcb08e40f4d34bd49d48974f1b01c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Dipeptidyl peptidase-like protein 6 (DPPX) antibody encephalitis is a rare autoimmune encephalitis. Diagnosis and treatment of DPPX remain challenging, particularly in patients with refractory disease. Herein, we report the first case of anti-DPPX en
Externí odkaz:
https://doaj.org/article/880cbd8db68c4f788c665415c02fbe23
Autor:
Cristina Scavone, Antonietta Anatriello, Isabella Baccari, Andrea Cantone, Daniele Di Giulio Cesare, Francesca Futura Bernardi, Ornella Moreggia, Valerio Liguori, Vincenzo Andreone, Giorgia Teresa Maniscalco, Annalisa Capuano
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (
Externí odkaz:
https://doaj.org/article/6e8f6ecdf90846e894bfbccc0a7fd25e